Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?

In science and in life, there's a special prestige that comes with being the first person or group to crack a previously intractable problem by using a cunning approach. Believe it or not, bragging rights matter to massive pharma players like Eli Lilly (LLY 0.61%), too. The question is, should such attainments matter to investors if the financial benefits from them are ambiguous?This isn't just an academic question. A few weeks ago, Lilly showed some proof that one of its clinical programs did what others c ...